A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs ACE 083 (Primary)
  • Indications Facioscapulohumeral muscular dystrophy
  • Focus Adverse reactions
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 28 Feb 2018 According to an Acceleron Pharma media release, results of second part of the trial are expected in the second half of 2019.
    • 27 Feb 2018 Planned number of patients changed from 76 to 92.
    • 27 Feb 2018 Planned End Date changed from 1 Apr 2019 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top